Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.

@article{Kroboth1985EffectsOE,
  title={Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.},
  author={Patricia Dowley Kroboth and Randall B. Smith and Raymond Rault and M R Silver and Michael I Sorkin and Jules B. Puschett and Randy P Juhl},
  journal={Clinical pharmacology and therapeutics},
  year={1985},
  volume={37 4},
  pages={453-9}
}
The kinetics of temazepam, 30 mg, were evaluated in 11 patients with end-stage renal disease. Age ranged from 18 to 65 years. On two occasions separated by 1 week, single oral 30 mg doses of temazepam were given once with water (TM) and once with 3600 mg aluminum hydroxide gel (TM + AHG). There were no significant differences in the maximum plasma concentration, the time to reach maximum concentration, or elimination rates between TM and TM + AHG dosing. In approximately half the subjects there… CONTINUE READING